Further studies on the effects of acamprosate on tolerance to the analgesic effects of morphine and NO synthesis in the brain

Jacqueline Sepúlveda¹*, Andrea Ortega¹, Jorge Roa², Enrique Contreras³

¹Department of Pharmacology, School of Biological Sciences, University of Concepción, Concepción, Chile; ²Corresponding Author: jsepulve@udec.cl ³Department of Physiology, School of Biological Sciences, University of Concepción, Concepción, Chile

Received 18 July 2013; revised 19 August 2013; accepted 9 September 2013

Copyright © 2013 Jacqueline Sepúlveda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The aim of this work was to investigate whether acamprosate modifies the expression of the enzyme responsible for neuronal NO synthesis (nNOS) in the nucleus accumbens (NAc) of mice chronically treated with morphine and during the abstinence syndrome induced by naloxone. The enzyme was monitored by the NADPH diaphorase method. The number of cells stained for NADPH diaphorase in the NAc of mice was counted in 40 µm thick coronal brain slices at 40X. The intensity of the histochemical reaction of stained cells from naive morphine plus saline and morphine plus acamprosate treated mice was analyzed by Image Pro Plus 4.5.1. Morphine administered in a slow release preparation increased the stain intensity of the positive neurons. The increase in the NADPH staining persisted after naloxone was given to mice chronically treated with morphine. Acamprosate antagonized the effects induced by chronic morphine treatment in the NAc of mice. These results indicate that up-regulation of nNOS in the NAc is a consequence of the sustained effects of morphine stimulation, which, in turn, may result from an increased in glutamate release during the abstinence syndrome.

Keywords: Morphine; Nitric Oxide; Nucleus Accumbens; Acamprosate

1. INTRODUCTION

Acamprosate is a taurine analog (calcium acetylo-motaurinate) that has received considerable attention for its ability to prevent relapse in abstinent alcoholics [1-5]. The mechanisms by which acamprosate decreases relapse to alcohol users are still poorly understood. It has been demonstrated that the drug reduces Ca²⁺ fluxes through voltage-operated channels and that it interacts with NMDA receptor-mediated glutamatergic neurotransmission in various brain regions with functional antagonistic properties [6-8]. The drug also inhibits the postsynaptic potential induced by glutamate in the neocortex and the hippocampus [9]. Further studies suggest that acamprosate may modify polyamine modulation of the NMDA receptor, but does not alter receptor function of the aminoacid [10].

The NAc is thought to be a determinant structure of the brain for the expression of rewarding effects of opioids [11,12]; additionally, neurochemical studies have demonstrated that the acute administration of morphine affects the concentrations of dopamine [13] acetylcholine [14], and that chronic morphine administration in rats augments glutamate release in the NAc, and in morphine-tolerant rats following naloxone administration [15].

There are now consisting evidences indicating that NO modulates several actions of opioids [16]. In mice and rats treated with morphine, the selective inhibitor of neuronal nitric oxide synthase (nNOS) 7-nitroindazole (7NI) has proven to suppress several actions induced by morphine, e.g. the activation of the extracellular signal-regulated kinase [17] and c-Fos expression in the striatum [18].

On the other hand, glutamate effects are associated with an increase in nitric oxide (NO) release [19,20]. Accordingly, an increase of glutamate effects must be ex-
pected to induce a greater expression of nitric oxide synthase (NOS), the enzyme responsible for NO release in the central nervous system [21].

NADPH diaphorase is responsible for the calcium/calmodulin-dependent synthesis of the guanylyl cyclase activator nitric oxide from L-arginine. The enzyme selectively labels a number of discrete populations of neurons throughout the nervous system. The NADPH diaphorase histochemical technique is used for labeling nNOS synthesis expression, considered to be a selective marker for distinct neural populations widely distributed throughout the CNS [22].

We have previously demonstrated that acamprosate reduces tolerance to the antinociceptive effect of morphine and the intensity of the abstinence behavior in rats chronically treated with the opiate [23]. Besides, it reduces the high levels of the excitatory amino acid observed in the nucleus accumbens (NAc) of morphine dependent rats during the withdrawal period [24]. The present work extends these studies and investigates whether acamprosate modifies the expression of NADPH diaphorase in the NAc of mice chronically treated with morphine and during the abstinence syndrome induced by naloxone, the opiate antagonist.

2. MATERIALS AND METHODS

2.1. Animals and Drugs

Male adult albino Swiss Webster mice 12 - 15 weeks of age, weighing 25 - 32 g from the animal reproduction laboratory of the Department of Pharmacology of the University of Concepcion were used in all experiments. Mice were housed in groups of 10 and maintained on a 12/12-h light/dark cycles at a room temperature of 22˚C with free access to food and water. All experiments were performed in accordance with institutional guidelines for the use of experimental animals and with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

The drugs used were morphine HCl (May and Baker, Dagenham, England), naloxone (Sigma, St. Louis, MO), and acamprosate (Lipha, Lyon, France). All other chemicals were purchased from Sigma, St. Louis, MO.

2.2. Induction of Morphine Dependence

For the induction of chronic morphine effects, the opiate was administered in a suspension of the following composition: morphine, as the base form, 300 mg, 4.2 ml liquid paraffin, and 0.8 ml sorbital sesquioleate mixed with 5 ml saline. After 30 h the animals were sacrificed and destined for histological analyses.

For the induction of the withdrawal syndrome, morphine (300 mg/kg) was administered 30 h before the i.p. administration of 4 mg/kg naloxone. To test the effect of acamprosate (100 mg/kg) on the expression of NADPH-diaphorase in morphine-dependent mice, this drug was i.p. administered during the chronic morphine treatment according to the following schedule: 30 min before and 12 and 24 h after the priming dose of morphine. Control groups were injected with the vehicle instead of acamprosate.

2.3. Histological Preparations

Mice destined for histological analyses were anesthetized with chloral hydrate (10 ml/kg solution 5% w/v) and after the induction of anesthesia; animals were injected with heparin (500 UI). Initially, isotonic saline solution (50 ml) for the intracardiac perfusion was used to flush out the blood, after which a mixture containing 4% (w/v) depolymerized paraformaldehyde in 0.1 M phosphate buffer (PBS), pH 7.3, was perfused for 20 min.

The brains were dissected out, cut into blocks, and post-fixed in the same solution for 4 hr at 4˚C. Tissue blocks were cryoprotected with 30% (w/v) sucrose in PBS until they sank, after which they were quickly frozen and stored at −80˚C. Tissue blocks were cut at 40 µm along coronal planes with a freezing sliding microtome (Leica SM 2000R, Germany) and collected in six series in cold PBS. One of these series was stained with the NADPH-diaphorase histochemical technique.

2.4. NADPH Histochemistry

Free-floating sections were rinsed in PBS (3 × 10 min) and incubated at 37˚C in the darkness in a medium containing 0.08% (w/v) Triton X-100, 0.8 M nitrobluetetrazolium, and 1 M β-NADPH in 0.1 M Tris-HCl, pH 8.0, for 90 - 120 min. The reaction was controlled under the microscope to avoid undesirable formation of formazan crystals, and stopped with cold PBS. Stained sections were mounted onto gelatin-coated slides, dried overnight at 37˚C, dehydrated, cleared with xylene, and cover slipped with Entellan®. Controls for specificity of the NADPH histochemistry were incubated without NADPH or without chromogen. No reaction product was observed in the tissue when incubated without NADPH or without chromogen.

2.5. Evaluation of NADPH Histochemistry

The boundaries of the region of the NAc were determined, and NADPH stained cells of this nucleus were counted. These planimetric analyses were performed in four consecutive sections from the same series, corresponding to Bregma levels ranging from 0.60 to 1.70 mm [25]. Rectangular frames were captured with a 40X objective and positive neurons were counted in each frame.
NADPH-histochemistry positive cells were counted only if the soma and dendrites were clearly distinguished (Carl Zeiss Series 237806 SNT Axioplan 2 Germany).

2.6. Quantitative Morphology

The population of cells stained for NADPH diaphorase was counted in 40 µm thick coronal brain slices at 40X. Seven toten fields of 2.8 µm² area, from four consecutive tissue sample sections, taken from 5 control animals and from mice from each of the experimental groups, were counted. Only cells with clear nuclear profiles, dendrites and clear borders were considered.

To ensure reliable comparisons among the different groups, one series from one animal from each group (i.e., series of sections from naive, morphine-, acamprosate- or saline-treated mice) was included in a parallel staining protocol using the same incubation medium. The intensity of the histochemical reaction of stained cells was analyzed by Image Pro Plus 4.5.1.

2.7. Statistical Analysis

The significance of the differences in the mean results to the different treatments were determined by analysis of variance (ANOVA) and confirmed with the Student-Newman-Keuls test. A level of probability of 0.05 was accepted as statistically significant.

3. RESULTS

3.1. NADPH Positive Neurons in the NAc

No significantly changes were found in the number of NADPH positive neurons in the NAc of mice treated with morphine, acamprosate, either alone or in combination with the opiate, when compared to the results observed in naive mice or in control animals injected with saline or vehicle. Similarly, no differences in the number of NADPH positive neurons were observed in morphine dependent mice at the end of the chronic morphine treatment or after naloxone administration (Figure 1).

3.2. Stain Intensity of NADPH Histochemistry

In contrast to the absence of differences in the number of neurons, the stain of positive neurons was more intense in the chronically morphine treated mice. Acamprosate significantly reduced the stain of neurons in vehicle injected rats. The drug also decreased the intensity of the stain with respect to values observed in mice treated with morphine and injected with naloxone.

Naloxone administration (20 min before the mice were sacrificed) did not change the morphine effects on the intensity of the staining (Figure 2).

4. DISCUSSION

Since the original work of Bredt et al. [26], it is accepted that there is a relationship between the activity of NOS and the increase of the expression of the enzyme. The neuronal isoform of the enzyme generates NO, a molecule recognized as a neurotransmitter in the central nervous system (CNS) that induces the production of cyclic GMP [27,28]. It has also been established that NADPH-diaphorase histochemical staining is a selective marker for distinct neural populations widely distributed throughout the CNS [22]. Different approaches have revealed that NADPH staining corresponds to nNOS expression [21].

In the present study, morphine induced an increase in the intensity of the NADPH staining of neurons of the NAc. The results suggest that the sustained effects of morphine are responsible for the up-regulation of NO generation.

Leza et al. have demonstrated that chronic morphine administration increases the calcium-dependent NOS activity in several areas of the brain [29]. These findings and a further study of the same laboratory [30] reporting an increase in NO synthase immunoreactivity suggest an up-regulation of the enzyme after morphine administra-
VEHICLE
MORPHINE
SALINE
ACAMPROSATE
MORPHINE+SALINE+NALOXONE
MORPHINE+ACAMPROSATE+NALOXONE

0.0
0.1
0.2
0.3
0.4
0.5
0.6

Stain Intensity (picocurie ± S.E.M)

(a)
(b)
(c)

Figure 2. Stain intensity of NADPH histochemistry of the neurons of NAc in mice. (a) Effect of chronic morphine administration. Morphine (300 mg/kg) was administered as a slow release preparation. (b) Effect of acamprosate treatment. Acamprosate (100 mg/kg) was i.p. administered 30 min before and 12 and 24 h after the vehicle. (c) Effect of acamprosate in naloxone-precipitated withdrawal of morphine treated-mice. Morphine (300 mg/kg) was administered 30 h before the i.p. administration of 4 mg/kg naloxone. Acamprosate (100 mg/kg) was i.p. administered 30 min before and 12 and 24 h after morphine. *Significantly higher than values observed in vehicle injected mice (P < 0.05). **Significantly lower than values observed in saline injected mice (P < 0.05). ***Significantly lower than values observed in the group injected with morphine, saline and naloxone (P < 0.001) and significantly higher than values observed in mice treated only with acamprosate (P < 0.05).

More recently, it was reported that NO synthase inhibition decreases tolerance development to morphine [31] and attenuates opioid withdrawal syndrome [32].

The exact mechanism by which morphine administration increases the expression of NADPH-diaphorase and NO synthesis is unknown, however, it has been suggested that the elevated intracellular concentration of calcium activates phospholipase C and protein kinase C [33]. The latter enzyme may enhance NMDA mediated calcium entry through glutamate, the crucial molecule involved in NO production [34].

Although the high glutamate levels during the withdrawal period are promptly decreased as a result of a counterbalance adaptation, the elevated expression of nNOS, which involves complex reactions in neuronal cells, may explain the persistence of some symptoms following the discontinuation of the drug administration. In addition, despite the increase of glutamate release observed during the abstinence period induced by naloxone [24], it is reasonable to expect that the induction of the abstinence syndrome by naloxone administration should not affect the intensity of the number of the stained neurons or the stain intensity because the animals were sacrificed 20 min after the induction of the syndrome, an interval not conclusive to increase gene expression and, consequently, to enhance NO synthase activity.

Acamprosate per se, or administered in morphine treated animals, reduced the intensity of the stained neurons, suggesting a decrease in the expression of neuronal NADPH diaphorase. Effects of acamprosate per se were also observed in other areas of the brain implicated in physical dependence of morphine, including frontal cortex, midbrain and cerebellum. The drug also reduced the intensity of the staining in the group of animals treated with morphine and injected with naloxone to precipitate a withdrawal syndrome. Therefore, it seems reasonable to suppose that acamprosate does not affect glutamate release but rather that its effects are consistent with a postsynaptic interference on glutamate-NMDA receptors, perhaps modulating the spermidine site of the NMDA receptor complex as has been suggested [35,36]. Consequently, the final result of acamprosate, administered in doses that decrease the intensity of morphine dependence, is a decrease in the synthesis of NO.

The present results suggest that glutamate and NO play a role in the neurochemical adaptation, which occurs in the brain during the administration of morphine, in particular on the NAc, a structure related with chronic drug consumption. The results also support the notion that acamprosate’s effects on chronic morphine responses may be partially assigned to the interaction with glutamate responses.

5. ACKNOWLEDGEMENTS

This work was supported by grant 203.032.011-1.0 from Vice-rectoria de Investigación y Desarrollo (VRID), Universidad de Concepción.

REFERENCES


http://dx.doi.org/10.1001/archpsyc.1996.0183008002300


[27] Garthwaite, J., Charles, S.L. and Chess-Williams, R. (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. *Nature*, **333**, 385. [http://dx.doi.org/10.1038/336385a0](http://dx.doi.org/10.1038/336385a0)


[34] Chen, L. and Huang, L.Y. (1991) Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. *Neuron*, **7**, 319-326. [http://dx.doi.org/10.1016/0896-6273(91)90270-A](http://dx.doi.org/10.1016/0896-6273(91)90270-A)
